← Back to headlines
Abivax secures $920 million for solo U.S. launch
French biotech Abivax has raised $920 million, providing enough cash to fund operations through 2029 and enabling a solo U.S. launch without needing a buyer.
10 Jul, 10:10 — 10 Jul, 10:10
